NCT01858740 · OUTCOME
Use of Additional Immune Suppressive Agents to Treat Chronic GVHD
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Immunosuppressive agents
- Interval / dispersion
- Not reported
- Time frame
- Up to 5 years
What was measured
Use of additional immune suppressive agents to treat chronic GVHD other than first line therapy. First line therapy is considered prednisone and tacrolimus/cyclosporin.
Groups in this outcome
Overall Study Patients Alive at D100
All participants in single arm study of CD45RA+ T cell depletion PBSC transplant and Methotrexate and tacrolimus for GVHD prophylaxis that were alive at D100
| Group | Source count |
|---|---|
| Overall Study Patients Alive at D100 | 18 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Overall Study Patients Alive at D100 | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 18
- units
- Participants
- description
- Use of additional immune suppressive agents to treat chronic GVHD other than first line therapy. First line therapy is considered prednisone and tacrolimus/cyclosporin.
- groups
- description
- All participants in single arm study of CD45RA+ T cell depletion PBSC transplant and Methotrexate and tacrolimus for GVHD prophylaxis that were alive at D100
- id
- OG000
- title
- Overall Study Patients Alive at D100
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- Use of Additional Immune Suppressive Agents to Treat Chronic GVHD
- type
- SECONDARY
- unit Of Measure
- Immunosuppressive agents
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle